We are close to achieving the production of a biomimetic functional skin and this advance is mainly due to the demand that is not limited to the field of regenerative medicine, the need for transplantation of this organ due to the aging of the population, but for ethical reasons related to the tests of safety and efficacy of new formulas in animal models by the cosmetic and pharmaceutical industries. The limitations involved in traditional 2D cell culture approaches and manual techniques for biomimetic generation have driven the use of innovative technologies such as 3D bioprinting. One of the main advantages of the bioprinted skin is the authenticity, scalability and reproducibility of tissues compared to conventional constructs, via precise positioning of multiple cell types and the inclusion of appendages. The models of bioprinted skins will serve as a platform for the development of new formulations, molecule testing, disease simulation, as well as an alternative to chronic wound biocuratives and clinical transplants. This paper reviews the state-of-the-art approaches available for skin model bioprinting, discusses the context of the drug-cosmetic industry in the adoption of these models and presents the characteristics of the project under development at Natura Cosmetics.